Return-path: <bounce-18416124_HTML-982008319-36137976-10831468-448@bounce.broadcastemail.asco.org>
Envelope-to: info@seeinindia.com
Delivery-date: Tue, 02 Jun 2015 14:29:58 +0000
Received: from mta.broadcastemail.asco.org ([64.132.92.206]:48897)
	by bh-in-11.webhostbox.net with esmtp (Exim 4.85)
	(envelope-from <bounce-18416124_HTML-982008319-36137976-10831468-448@bounce.broadcastemail.asco.org>)
	id 1YznCW-003DdI-Tb
	for info@seeinindia.com; Tue, 02 Jun 2015 14:29:58 +0000
Received: by mta.broadcastemail.asco.org id hdmuua163hs9 for <info@seeinindia.com>; Tue, 2 Jun 2015 08:29:21 -0600 (envelope-from <bounce-18416124_HTML-982008319-36137976-10831468-448@bounce.broadcastemail.asco.org>)
From: "Daily News" <dailynews@asco.org>
To: <info@seeinindia.com>
Subject: Results from ROMANA 1/2 and PALOMA3, TAPUR and NCI-MATCH Trial Plans Announced, and More
Date: Tue, 02 Jun 2015 08:29:20 -0600
List-Unsubscribe: <mailto:leave-fc5015787165027c77101f2d205921-fe271d7877640475761579-fe551776746703747212-fe6015707d670579731c-ff5f10747d@leave.broadcastemail.asco.org>
MIME-Version: 1.0
x-job: 10831468_36137976
Message-ID: <55b5f895-2593-413e-bb2a-1eff228f9ef7@xtinmta199.xt.local>
Content-Type: multipart/alternative;
	boundary="HDjakpwv4zyK=_?:"
X-Authenticated_sender: 

This is a multi-part message in MIME format.

--HDjakpwv4zyK=_?:
Content-Type: text/plain;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

To view this email as a web page, go to the link below, or copy and paste it into your browser's address window.
http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59107505519621a40b9e7b8f9d76da77a95237ce77c6cd096fda127b48be5cee0aASCO
http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59246b02a61149c711ae7f800597ac256ce0c7248beea8d21c235d1d545569717c 

Advertisement

 

http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f590f9bd9dbbd9b889344dea4035e44683f6da76db74fd95ac9cc05f10e4520b9da 

http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59654bb828adb13cd169b3abea825512499dd1ac57b6865801ec7f5d861f4c8b06 
ASCO, NCI Announce Plans for Precision Medicine Trials  

http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59654bb828adb13cd169b3abea825512499dd1ac57b6865801ec7f5d861f4c8b06 
 
At a press briefing on Monday, June 1, plans were announced for ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) study (presented by Dr. Richard L. Schilsky [pictured]) and the NCI-MATCH: Molecular Analysis for Therapy Choice trial (EAY131). 


http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59654bb828adb13cd169b3abea825512499dd1ac57b6865801ec7f5d861f4c8b06 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59ee70a4324c73483c243f0a84085ed2d63f1b42287868e098fbcc621e88f7b416 
 
http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59ee70a4324c73483c243f0a84085ed2d63f1b42287868e098fbcc621e88f7b416 
Anamorelin Effectively Targets Cachexia in Patients with Advanced NSCLC 

Treatment with anamorelin, a highly selective ghrelin receptor agonist, resulted in significant increases in lean body mass and body weight in patients with advanced non-small cell lung cancer and cachexia compared with placebo, according to the results of the ROMANA 1 and 2 trials, presented byDr. Jennifer S. Temel (pictured) (Abstract 9500). 


http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59ee70a4324c73483c243f0a84085ed2d63f1b42287868e098fbcc621e88f7b416 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f007b285d95607026041fc5d95a0479fcd199cca5b85eb8d546e51bd868c9b4e32 
 
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f007b285d95607026041fc5d95a0479fcd199cca5b85eb8d546e51bd868c9b4e32 
Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks for Bone Metastases 

Zoledronic acid administered every 12 weeks was noninferior to an every 4-week regimen in the phase III CALGB 70604 trial of patients with breast cancer, prostate cancer, or multiple myeloma with bone metastases (Abstract 9501). Andrew L. Himelstein (pictured) presented the results during the Patient and Survivor Care Oral Abstract Session.


http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f007b285d95607026041fc5d95a0479fcd199cca5b85eb8d546e51bd868c9b4e32 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05e7b801840a78bed2fea8d0c49565cab36ab39f2637929600a553a7cc8615696 
 
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05e7b801840a78bed2fea8d0c49565cab36ab39f2637929600a553a7cc8615696 
CDK 4/6 Inhibitor Yields PFS Improvement for Patients with HR+/HER- Breast Cancer  

According to results of the PALOMA3 study, presented by Dr. Nicholas C. Turner (pictured), the addition of palbociclib to fulvestrant conferred significant benefit for women with hormone-positive, HER-negative advanced breast cancer for whom prior endocrine therapy had failed (Abstract LBA502).


http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05e7b801840a78bed2fea8d0c49565cab36ab39f2637929600a553a7cc8615696 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0040636a469b5365fcbf0c2f59ae2e24dca9373642494cb65762c7cf68137e6cf 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0040636a469b5365fcbf0c2f59ae2e24dca9373642494cb65762c7cf68137e6cf 

Developing Resource-Stratified Guidelines in Oncology to Improve Cancer Care Worldwide
 

Drs. Gilberto Lopes, Alexandru Eniu, and Nagi El Saghir (from left to right) discuss efforts to create resource-stratified guidelines to help fill health care needs and maximize outcomes in limited-resource regions.


http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0040636a469b5365fcbf0c2f59ae2e24dca9373642494cb65762c7cf68137e6cf 
Read the Full Story >> 

 
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f078b188cf84599fc3650c7e36f295128d2e086400a8e04e9579d109ab1f7a56a8 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f078b188cf84599fc3650c7e36f295128d2e086400a8e04e9579d109ab1f7a56a8 

Stop the Insanity: Changing Our Approach to Federal Biomedical Research Funding
 

Dr. Blase N. Polite (pictured) discusses how NIH funding for biomedical research continues to decrease and presents potential solutions to improve the federal funding system.


http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f078b188cf84599fc3650c7e36f295128d2e086400a8e04e9579d109ab1f7a56a8 
Read the Full Story >> 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05bd6e821ef5ed8407f0178cc285c0422b16b49fc12e5945f72f013063f14476d 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05bd6e821ef5ed8407f0178cc285c0422b16b49fc12e5945f72f013063f14476d 

PQRS Reporting for Medical Oncologists
 

Dr. Carolyn B. Hendricks (pictured) discusses how quality reporting through the CMS Physician Quality Reporting System may improve care for oncology practices through internal benchmarking and by providing important feedback.


http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05bd6e821ef5ed8407f0178cc285c0422b16b49fc12e5945f72f013063f14476d 
Read the Full Story » 

 
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0277309e7dd29fef7029db4b2b26a16d7c7d142d0f0ffca1bdc6fa20e04c57786 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0277309e7dd29fef7029db4b2b26a16d7c7d142d0f0ffca1bdc6fa20e04c57786 

How Oncologists Can Better Support Family Caregivers
 

Dr. Lidia Schapira (pictured) reflects on how family caregivers are valuable partners in caring for patients with cancer as they heal after surgery or recover from grueling systemic therapies.


http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0277309e7dd29fef7029db4b2b26a16d7c7d142d0f0ffca1bdc6fa20e04c57786 
Read the Full Story » 

http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f093a0537d689e7d195e35997933afa9b89edc4d18837f8b610913bd894a7ed7e1 
ASCO Daily News Home
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05d9565a11352f2b87fb8588c892a3d2c3ec5599a5336672efb25c7c0859f1cba 
 | 
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f0a29d244352814a0cf3c42382f847f57769b19ce7637a6c52d751bf1af09b4f6f 
Session Coverage  | 
http://click.broadcastemail.asco.org/?qs=e0b1236e4f4676f05581615955709819d90633c8827f7d8c04f6760b4465f6e3a00caeda1a0fd96c 
Expert Editorials 

http://click.broadcastemail.asco.org/?qs=4aad58e5f850e9810a92f7bdab6636626d4145e399e0badcc548abd8d06021d2bb6d1c62b2113ea4 
Grants and Awards  | 
http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981439d32f57753d0ab0c6c02496217cca9e3bb48508e44d801636ede8bc5c796cd 
am.asco.org 

Connect with us:
http://click.broadcastemail.asco.org/?qs=4aad58e5f850e9810ed963eae93a47f33d6cb0f430b45d0ee751c8a871e85cc2cf701fbacc07f241 

http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981a7e5e58d0307dbea85471cf1f0ece0e97645df2046f1a4db51024bca809ab539 

http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981f6170851507d723fded970e4988a7c52c7b887fea2209ebd295b7ba0540d3fdf 

http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981a1d0028aa388c657b2739ac345c48477656dc4aa2b12f162e76dd9705873a1d1 
Forward to a Colleague 
http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981a1d0028aa388c657b2739ac345c48477656dc4aa2b12f162e76dd9705873a1d1 

 
http://click.broadcastemail.asco.org/?qs=4aad58e5f850e9819c2ee4313b7e4b30d88a3460cb7740334d24dea5cc98fbcd6c5fe9c0fabf8cf4 
Advertisement

http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981f8b5d3f42423433e4f8408a2425415e4f64bfd1684d5a8c51a02722158561227 

Advertisement








You are receiving this email because you have an existing relationship
with ASCO.  Visit your personalized 
http://click.broadcastemail.asco.org/?qs=4aad58e5f850e981a271c208d5b4d98fe62249c05967409d399dd5cdd4c7d33ccbf96020174041e4 
Preference Center  to unsubscribe or to select
your preferences for receiving ASCO promotional email.  Please do
not reply to this email.  

This email was sent by: American Society of Clinical Oncology

2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA



--HDjakpwv4zyK=_?:
Content-Type: text/html;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<div style="display:block;width:100%;text-align:center;font-family: Verdana, sans-serif;font-size:10px;color:#444444;padding:8px 0;margin:auto;">
	To view this email as a web page, go   <a href="http://click.broadcastemail.asco.org/?qs=839c61e1d49f264ee485ebc7ab1cf688c8ec2c453f999caefa3402e0bca93bd087f8974cbacccb75" > here</a>.
</div><!DOCTYPE html>
<html lang="en">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <title>ASCO</title>

    <style>
        
        body {margin:0; padding:0; -webkit-text-size-adjust:none; -ms-text-size-adjust:none;} img{line-height:100%; outline:none; text-decoration:none; -ms-interpolation-mode: bicubic;} a img{border: none;} #backgroundTable {margin:0; padding:0; width:100% !important; } a, a:link{color:#318786; text-decoration: none;} table td {border-collapse:collapse;} span {color: inherit; border-bottom: none;} span:hover { background-color: transparent; }

    </style>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">


    <table id="backgroundTable" width="100%" cellspacing="0" cellpadding="0" border="0" style="background:#d8d8d8;">
        <tr>
            <td class="body" align="center" valign="top" style="background:#d8d8d8;" width="100%">
                <table cellpadding="0" cellspacing="0">
                    <tr>
                        <td class="banner" width="826" align="center" style="background: #d8d8d8; padding-top: 16px;">
                            <table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><a   title="Banner Ad" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c696c0f934a57c490457c0792559eced8ece3d1edf918d28afc9249166b4eb734f9"><img width="728" height="90" border="0" mdid="41bc58fb-a9b4-4e7c-aabf-08f737ba5ad2" style="width: 728px; height: 90px; border-color: #000000; margin: 0px;" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/3-728x90-OAK_V09_FOF.jpg" title="3-728x90-OAK_V09_FOF" alt="3-728x90-OAK_V09_FOF" /></a><br />Advertisement
</div></td></tr></table></td></tr></table>&nbsp;
                        </td>
                    </tr>
                    <tr>
                       
                    </tr>
                    <tr>
                        <td class="main" width="826" align="center">
                            <table cellpadding="0" cellspacing="0">
	<tr>
        <td class="header" width="826" align="left">
            
        </td>
    </tr>
    <tr>
    	<td class="subheader" width="826" align="left">
    		<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69bcb926ac2e71389112ecb476b044ec41687e0b4d0cd8512b91bfce7b7dce74a0" title="AM2015 Daily News"  ><img width="826" height="115" border="0" alt="AM15daily-banner-826x115-eDigest" title="AM15daily-banner-826x115-eDigest" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AM15daily-banner-826x115-eDigest.png" style="width: 826px; height: 115px; border-color: #000000; margin: 0px;" /></a></td></tr></table></td></tr></table>
    	</td>
    </tr>
    <tr>
    	<td width="826" style="background: #d8d8d8;">
    		<table cellpadding="0" cellspacing="0">
    			<tr>
    				<td style="padding: 16px;">
    					<table cellpadding="0" cellspacing="0">
    						<tr>
    							<td width="618" valign="top">
    								<table cellpadding="0" cellspacing="0">
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a   title="ASCO, NCI Announce Plans for Precision Medicine Trials" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69e630c8f8cc7eaa7ce76cfcab3151c76f58fc91028ee52c8c53e17ad35097c03e">ASCO, NCI Announce Plans for Precision Medicine Trials </a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a   title="ASCO, NCI Announce Plans for Precision Medicine Trials" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69e630c8f8cc7eaa7ce76cfcab3151c76f58fc91028ee52c8c53e17ad35097c03e"><img width="284" height="148" thid="290751a8-7c99-4e0a-9fef-6a10217a90e0" title="Schilsky_168x144" style="display: block; border: 0px none; width: 284px; height: 148px; margin: 0px;" alt="Schilsky_168x144" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Schilsky_284x188.jpg" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
At a press briefing on Monday, June 1, plans were announced for ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) study (presented by Dr. Richard L. Schilsky [pictured]) and the NCI-MATCH: Molecular Analysis for Therapy Choice trial (EAY131). 
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title="ASCO, NCI Announce Plans for Precision Medicine Trials" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69e630c8f8cc7eaa7ce76cfcab3151c76f58fc91028ee52c8c53e17ad35097c03e">Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c691389897e4ef41d8a4c9b0db8c33a27c622c9bf25d88d1a29832edc8f405298be" title="Anamorelin Effectively Targets Cachexia in Patients with Advanced NSCLC"  ><img width="168" height="174" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" alt="Tue.WrapUp.9500_Temel" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Tue.WrapUp.9500_Temel.jpg" title="Tue.WrapUp.9500_Temel" thid="06e1c11f-27b7-43ac-ba76-6f37a2cdd1ad" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a   title="Anamorelin Effectively Targets Cachexia in Patients with Advanced NSCLC " style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69efd5a6b9ee508beb20dad7412712ce401af4bbe90f5769413961ffd8dc981e37">Anamorelin Effectively Targets Cachexia in Patients with Advanced NSCLC</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Treatment with anamorelin, a highly selective ghrelin receptor agonist, resulted in significant increases in lean body mass and body weight in patients with advanced non-small cell lung cancer and cachexia compared with placebo, according to the results of the ROMANA 1 and 2 trials, presented by  Dr. Jennifer S. Temel (pictured) (Abstract 9500). 
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a   title="https://am.asco.org/anamorelin-effectively-targets-cachexia-patients-advanced-nsclc" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69b424514f0d6f3a2f18fcfe7cd9bc7aacddaf4327ae6d5606e66daa1a10f0f725">Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a   title="Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks for Bone Metastases" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69831eb84edcfa3748bd53049311c815c4279f13e4a4d5794bedbcdc8027a97a16"><img width="168" height="174" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Tue.WrapUp.9501_Himelstein.jpg" title="Tue.WrapUp.9501_Himelstein" alt="Tue.WrapUp.9501_Himelstein" thid="1bb95722-f035-4e6c-9514-f5dd495aca1c" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a   title="Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks for Bone Metastases" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69831eb84edcfa3748bd53049311c815c4279f13e4a4d5794bedbcdc8027a97a16">Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks for Bone Metastases</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Zoledronic acid administered every 12 weeks was noninferior to an every 4-week regimen in the phase III CALGB 70604 trial of patients with breast cancer, prostate cancer, or multiple myeloma with bone metastases (Abstract 9501). Andrew L. Himelstein (pictured) presented the results during the Patient and Survivor Care Oral Abstract Session.
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a   title="Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks for Bone Metastases" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69831eb84edcfa3748bd53049311c815c4279f13e4a4d5794bedbcdc8027a97a16">Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a   title="CDK 4/6 Inhibitor Yields PFS Improvement for Patients with HR+/HER- Breast Cancer " href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69c006df80e0e0466d939a61f9be7506e35a32568bb6cdf346c62b55f4108626b8"><img width="168" height="174" title="Tue.WrapUp.LBA502_Turner" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Tue.WrapUp.LBA502_Turner.jpg" alt="Tue.WrapUp.LBA502_Turner" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" thid="5eac805e-2ce7-44f8-8d53-6fa8a1f480c2" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69c006df80e0e0466d939a61f9be7506e35a32568bb6cdf346c62b55f4108626b8" style="text-decoration: none; color: #318786;" title="CDK 4/6 Inhibitor Yields PFS Improvement for Patients with HR+/HER- Breast Cancer "  >CDK 4/6 Inhibitor Yields PFS Improvement for Patients with HR+/HER- Breast Cancer </a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
According to results of the PALOMA3 study, presented by Dr. Nicholas C. Turner (pictured), the addition of palbociclib to fulvestrant conferred significant benefit for women with hormone-positive, HER-negative advanced breast cancer for whom prior endocrine therapy had failed (Abstract LBA502).
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c69c006df80e0e0466d939a61f9be7506e35a32568bb6cdf346c62b55f4108626b8" style="text-decoration: none; color: #318786;" title="CDK 4/6 Inhibitor Yields PFS Improvement for Patients with HR+/HER- Breast Cancer "  >Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" style="padding-bottom: 16px;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td width="301" valign="top">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c696ff287ec8ff787a718deb067e3899182b6c1ec5585d2aef40dfad553e26c2d7d" title=" Developing Resource-Stratified Guidelines in Oncology to Improve Cancer Care Worldwide"  ><img width="301" height="190" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/combined+international.jpg" style="display: block; border: 0px none; width: 301px; height: 190px; margin: 0px;" title="combined international" alt="combined international" thid="06e95032-53a3-491f-90be-086f83326588" /></a>
									</td>
								</tr>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td style="padding: 20px 24px;">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
															<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c696ff287ec8ff787a718deb067e3899182b6c1ec5585d2aef40dfad553e26c2d7d" style="text-decoration: none; color: #318786;" title=" Developing Resource-Stratified Guidelines in Oncology to Improve Cancer Care Worldwide"  >
															Developing Resource-Stratified Guidelines in Oncology to Improve Cancer Care Worldwide
															</a>
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
															Drs. Gilberto Lopes, Alexandru Eniu, and Nagi El Saghir (from left to right) discuss efforts to create resource-stratified guidelines to help fill health care needs and maximize outcomes in limited-resource regions.
															<br />
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c696ff287ec8ff787a718deb067e3899182b6c1ec5585d2aef40dfad553e26c2d7d" style="text-decoration: none; color: #318786;" title=" Developing Resource-Stratified Guidelines in Oncology to Improve Cancer Care Worldwide"  >Read the Full Story &raquo;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
						<td width="16" style="font-size: 1px;">&nbsp;</td>
						<td width="301" valign="top">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c6955fa9f1ef92e1ace001a10c1bd0bb283a447fb2fdb3c770a9ed48c0a5086212e" title=" Stop the Insanity: Changing Our Approach to Federal Biomedical Research Funding"  ><img width="301" height="190" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Polite_Blase.jpg" alt="Polite_Blase" style="display: block; border: 0px none; width: 301px; height: 190px; margin: 0px;" title="Polite_Blase" thid="31f6cfde-6910-4f81-90e9-74c6a5af2e8d" /></a>
									</td>
								</tr>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td style="padding: 20px 24px;">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
															<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c6955fa9f1ef92e1ace001a10c1bd0bb283a447fb2fdb3c770a9ed48c0a5086212e" style="text-decoration: none; color: #318786;" title=" Stop the Insanity: Changing Our Approach to Federal Biomedical Research Funding"  >
															Stop the Insanity: Changing Our Approach to Federal Biomedical Research Funding
															</a>
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
															Dr. Blase N. Polite (pictured) discusses how NIH funding for biomedical research continues to decrease and presents potential solutions to improve the federal funding system.
															<br /><br>
																											</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=8b95e80a916f5c6955fa9f1ef92e1ace001a10c1bd0bb283a447fb2fdb3c770a9ed48c0a5086212e" style="text-decoration: none; color: #318786;" title=" Stop the Insanity: Changing Our Approach to Federal Biomedical Research Funding"  >Read the Full Story &raquo;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"></td>
    									</tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" style="padding-bottom: 16px;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td width="301" valign="top">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="301" align="center" style="background: #ffffff none repeat scroll 0% 0%;">
									<a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612b25754eab5adc8cc046ef100aefe9b7999cb666cf1a91a8af5c96ff481485ff6" title=" PQRS Reporting for Medical Oncologists"  ><img width="225" height="190" thid="8267f90b-587f-466d-8797-954083111fa2" style="display: block; border: 0px none; width: 225px; height: 190px; margin: 0px;" alt="Hendricks_Carolyn" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Hendricks_Carolyn.jpg" title="Hendricks_Carolyn" dontmaintainaspect="true" /></a>
									</td>
								</tr>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td style="padding: 20px 24px;">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
															<a   title=" PQRS Reporting for Medical Oncologists" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612b25754eab5adc8cc046ef100aefe9b7999cb666cf1a91a8af5c96ff481485ff6">
															PQRS Reporting for Medical Oncologists
															</a>
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
															Dr. Carolyn B. Hendricks (pictured) discusses how quality reporting through the CMS Physician Quality Reporting System may improve care for oncology practices through internal benchmarking and by providing important feedback.
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title=" PQRS Reporting for Medical Oncologists" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612b25754eab5adc8cc046ef100aefe9b7999cb666cf1a91a8af5c96ff481485ff6">Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
						<td width="16" style="font-size: 1px;">&nbsp;</td>
						<td width="301" valign="top">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="301" align="center" style="background: #ffffff none repeat scroll 0% 0%;">
									<a   title=" How Oncologists Can Better Support Family Caregivers" href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612e9da3bb59660b671ea4080fb021b965dbdacc81772af62128375dff4c079575b"><img width="175" height="190" thid="49c3c99f-9679-43ad-a92e-4d02638eb22e" style="display: block; border: 0px none; width: 175px; height: 190px; margin: 0px;" alt="AMDN15.EE.Schapira" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AMDN15.EE.Schapira.jpg" title="AMDN15.EE.Schapira" /></a>
									</td>
								</tr>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td style="padding: 20px 24px;">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
															<a   title=" How Oncologists Can Better Support Family Caregivers" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612e9da3bb59660b671ea4080fb021b965dbdacc81772af62128375dff4c079575b">
How Oncologists Can Better Support Family Caregivers
</a>
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Dr. Lidia Schapira (pictured) reflects on how family caregivers are valuable partners in caring for patients with cancer as they heal after surgery or recover from grueling systemic therapies.
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title=" How Oncologists Can Better Support Family Caregivers" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612e9da3bb59660b671ea4080fb021b965dbdacc81772af62128375dff4c079575b">Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="border-top: 1px solid #ffffff; border-bottom: 2px solid #ffffff; padding: 12px 0px; background: #d2e8e2 none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a   href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612e188a85378c70b13881fe4c663748ecf46d48f5f4a5ac84c910a51b746397f2f" style="text-decoration: none; color: #318786;" title="https://am.asco.org/daily-news"><i>ASCO Daily News</i> Home</a><a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612bdf6c0b8ebef3f394cf0daaeaa9d3205c9d18f4579194e23e16edea3f77bfae38cf7fed08ccb10a9" title="ASCO Daily News Home"  ></a> | <a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc56125a7104a4fa0a668b0d7bc39aa255189dcb027ab8058545f79213433f37eb93a2d7c6d15afbb8f715" style="text-decoration: none; color: #318786;" title="Session coverage"  >Session Coverage</a> | <a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612e574658e7079c3d2c23da6b4dfcd9b11f6c2b59720ae0b9856327a569ca95d07d0f48c72c9feea1e" style="text-decoration: none; color: #318786;" title="Expert editorials"  >Expert Editorials</a>
						</td>
					</tr>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612e008b58b7d3013ad11f22952440c0ba8ad5b302c1c523de05aa8ccc0c7b9c33c3b5f767ac61445fa" style="text-decoration: none; color: #318786;" title="Grants and Awards"  >Grants and Awards</a> | <a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc561293a22070de9ade9bc0f5ff95f6528de12af7a9cb2711bef90c4cfaf733947d33198384039f5e46bc" style="text-decoration: none; color: #318786;" title="am.asco.org"  >am.asco.org</a>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="padding: 12px 0px; background: #efefef;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">Connect with us:</td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc56129b5046a9d71f33e11831282297da1ae9aed543dc953384dd5fadd605a56041cbc7e8329674a2926c" title="Twitter"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_11.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=1d7e7a75fafc5612cdd74d2ecfedc33158546183467265bd3a030e26072282ede89d1c804a1b5f4ee6505859c8ec1772" title="Facebook"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_13.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59a3e35fa330303e3d32f9e804551a57a3a67bc3b39f7022abb4a3e7de50843598c2f2c8d5ed8645e8" title="Linkedin"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_15.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 20px;"></td>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">
						<a href="http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59fc2803fe25e63a9aefb0763ddc813850a76500b1e908f15640e7b01d61fdc370" style="text-decoration: none; color: #318786;">Forward to a Colleague</a>
						</td>
						<td><a href="http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59fc2803fe25e63a9aefb0763ddc813850a76500b1e908f15640e7b01d61fdc370"><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_19.jpg" alt="Email" style="display: block; border: 0px;" /></a></td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
    								</table>
    							</td>
    							<td width="16" style="font-size: 1px; min-width: 16px;">&nbsp;</td>
    							<td width="160" valign="top">
    								<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><a href="http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59b59aed49bf038795736bdf128ef5d87d69ee21aafb56502eb5eedf8f68f745a0" title="Sidebar Ad"  ><img width="160" height="600" border="0" alt="3-160x60-OAK_V08_FOF" title="3-160x60-OAK_V08_FOF" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/3-160x60-OAK_V08_FOF.jpg" style="width: 160px; height: 600px; border-color: #000000; margin: 0px;" mdid="744513f0-4018-4889-a913-1498d3d5ce44" /></a></div>
<div align="center">Advertisement</div></td></tr></table></td></tr></table>
    							</td>
    						</tr>
    					</table>
    				</td>
    			</tr>
    		</table>
    	</td>
    </tr>
    <tr>
    	<td class="disclaimer" width="826" align="center">
    		<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><a href="http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f59a821ea205d80fa4847ce240b28d23edb90750402b1bc2c5c78f844c5291e2011" title="ASCO Connection"  ><img width="728" height="90" border="0" alt="AC-web-ad-728x90_2015-05-26" title="AC-web-ad-728x90_2015-05-26" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AC-web-ad-728x90_2015-05-26.png" style="width: 728px; height: 90px; border-color: #000000; margin: 0px;" mdid="67f6910f-5001-4b95-9c31-789b4bfe6923" /></a>
<br />Advertisement</div></td></tr></table></td></tr></table>
    	</td>
    </tr>
</table>
                        </td>
                    </tr>
                    <tr>
                      
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
    </table>

    <!-- Exact Target tracking code -->
    <img src="http://click.broadcastemail.asco.org/open.aspx?ffcb10-fe551776746703747212-fdc61574706c037c7112727664-fe6015707d670579731c-fe6415787165027c7710-fe271d7877640475761579-ff5f10747d" width="1" height="1">

</body>
 <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<title></title>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">
<body>


<div width="850" style="margin-left: auto; margin-right: auto; width: 850px; text-align: left;">

You are receiving this email because you have an existing relationship
with ASCO.&nbsp; Visit your personalized <a
href="http://click.broadcastemail.asco.org/?qs=ae7e85ec9cb86f596e72e2201c04dc8091d5c93669d1cc3bb9b0cd8112891adada82a3e419b8274f"
target="_blank">Preference Center</a> to unsubscribe or to select
your preferences for receiving ASCO promotional email.&nbsp; Please do
not reply to this email.&nbsp; <br>
This email was sent by: American Society of Clinical Oncology<br>
2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA<br></div>
</body>
</body>
</html>

--HDjakpwv4zyK=_?:--

